Date: 2015-03-04
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Astellas Pharma (Japan)
Product: ASP4132
Action mechanism:
Disease: lymphoma, advanced refractory solid tumors
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132. The study will also determine the pharmacokinetics (PK) of ASP4132 and evaluate the preliminary antitumor activity.(NCT02383368)
Latest
news: * On March 3, 2015, a Phase I trial sponsored by Astellas was published on the NIH website ClinicalTrials.gov for ASP4132 and is currently recruiting participants.
